

Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis

Takamasa Ohki¹ · Koki Sato¹ · Mari Yamagami¹ · Daisaku Ito¹ · Tomoharu Yamada¹ · Koki Kawanishi¹ · Kentaro Kojima¹ · Michiharu Seki¹ · Nobuo Toda¹ · Kazumi Tagawa¹

Published online: 4 January 2016
© Springer International Publishing Switzerland 2015

Erratum to: Clin Drug Investig (2015) 35:751–759 DOI 10.1007/s40261-015-0333-3

The author would like to make the below changes in the original article which was incorrectly published.

Page 751, Abstract, Results, line 2 which previously read:

Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, $P = 0.04$).

Should read:

Although median tumor size was similar between groups, the median tumor number was significantly higher in the S-TACE versus TACE-alone group (7 vs. 4, $P < 0.01$).

Page 751, Abstract, Results, line 9 which previously read:

Median PFS (189 vs. 106 days, $P = 0.02$) and median overall survival time (861 vs. 467 days, $P = 0.01$) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone.

Should read:

Median PFS (189 vs. 106 days, $P < 0.01$) and median overall survival time (861 vs. 467 days, $P < 0.01$) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone.

The online version of the original article can be found under doi:[10.1007/s40261-015-0333-3](https://doi.org/10.1007/s40261-015-0333-3).

✉ Takamasa Ohki
anb72547@nifty.com

¹ Department of Gastroenterology, Mitsui Memorial Hospital, Kanda-Izumi-cho 1, Chiyoda-ku, Tokyo 101-8643, Japan

Page 752, Section 1, 1st column, line 46, the references which previously read:

“[18]”

Should read:

“[19]”

Page 753, Section 2.1, 2nd paragraph, line 1 which previously read:

Of the 95 patients, 24 patients who were previously non-responsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).

Should read:

Of the 95 patients, 24 patients who were previously non-responsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).

Page 754, Section 3, 2nd column, line 10 which previously read:

The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (2 [1–3] vs. 1 [0–2], $P < 0.01$) and radiofrequency ablation (4 [1–5] vs. 1 [0–3], $P < 0.01$).

Should read:

The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (3 [range 2–4] vs. 2 [range 2–3], $P < 0.01$) and radiofrequency ablation (4 [range 1–5] vs. 1 [range 0–3], $P < 0.01$).

Page 755, Table 1, column 2, last row which previously read:

2 (1–3)

Should read:

3 (2–4)
Page 755, Table 1, column 3, last row which previously read:

1 (0–2)

Should read:

2 (2–3)

Page 756, Section 4, 2nd column, line 2, the references which previously read:

“[22, 50, 51].”

Should read:

“[24, 50, 51].”

Page 756, Section 4, 2nd column, line 13, the reference which previously read:

“[52].”

Should read:

“[51].”

Page 756, section 4, 2nd column, line 16, the reference which previously read:

“[31]”

Should read:

“[32]”

Page 756, Section 4, 2nd column, line 18, the references which previously read:

“[32, 33, 52, 53].”

Should read:

“[32, 33, 51, 52].”

Page 756, Section 4, 2nd column, line 26, the reference which previously read:

“[54].”

Should read:

“[53].”

Page 758, References: There were errors in the reference list. The corrected reference list is re-published below:

1. GLOBOCAN 2012 v1.0. Estimated cancer incidence, mortality, and prevalence worldwide. <http://globocan.iarc.fr>. Accessed 4 Jun 2015.

2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. *Lancet*. 2003;362:2089–94.

3. Yuen MF, Hou JL, Chutaputti A. Asia Pacific Working Party on prevention of hepatocellular carcinoma. Hepatocellular carcinoma in the Asia Pacific region. *J Gastroenterol Hepatol*. 2009;24:346–53.

4. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. *Hepatol Res*. 2007;37:S88–94.

5. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol*. 2013;47:S2–6.

6. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. *J Gastroenterol*. 2009;44:102–7.

7. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. *Hepatol Res*. 2007;37:S95–100.

8. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y. Development of evidencebased clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. *Hepatol Res*. 2008;38:37–51.

9. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int*. 2010;4:439–74.

10. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology*. 2004;127:S35–50.

11. Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Nae-shiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Recent trend of clinical features in patients with hepatocellular carcinoma. *Hepatol Res*. 2012;42:368–75.

12. Nishikawa H, Osaki Y. Non-B, non-C hepatocellular carcinoma. *Int J Oncol*. 2013;43:1333–42.

13. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet*. 2003;362:1907–17.

14. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. *Hepatol Res*. 2007;37:676–91.

15. Tang ZY. Relapse and metastasis—a key point in research of primary hepatocarcinoma. *Zhonghua Gandan Waike Zazhi*. 1999;5:3–5.

16. Qiu LD, Ding YT. The research and therapy improvement of recurrence and metastasis of hepatocellular carcinoma. *Gandan Waike Zazhi*. 2001;9:6–7.

17. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011;53:1020–2.

18. Cheng HY, Wang X, Chen D, Xu AM, Jia YC. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. *World J Gastroenterol*. 2005;11:3644–6.

19. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet*. 2002;359:1734–9.

20. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for

- unresectable hepatocellular carcinoma. *Hepatology*. 2002;35:1164–71.
21. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. *Dig Dis*. 2011;29:339–64.
22. Cheng AL, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Park JW. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. *Liver Int*. 2014;34:174–83.
23. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*. 2012;56:908–43.
24. Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, Yamakado K, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Liver Cancer Study Group of Japan. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. *Oncology*. 2014;87:22–31.
25. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomini A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. *Am J Gastroenterol*. 2008;103:914–21.
26. Shim JH, Park JW, Kim JH, An M, Kong SY, Nam BH, Choi JI, Kim HB, Lee WJ, Kim CM. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. *Cancer Sci*. 2008;99:2037–44.
27. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. *Mol Cancer Ther*. 2008;7:3129–40.
28. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. *J Clin Oncol*. 2011;29:3960–7.
29. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res*. 2004;64:7099–109.
30. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Gretten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*. 2008;359:378–90.
31. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009;10:25–34.
32. Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T. Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. *J Gastroenterol*. 2014;49:932–40.
33. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Kanai F, Yoshikawa M, Yokosuka O. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. *Oncology*. 2014;87:330–41.
34. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol*. 2012;57:821–9.
35. Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. *Exp Ther Med*. 2012;4:381–6.
36. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevilla-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. *Aliment Pharmacol Ther*. 2011;34:205–13.
37. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, Gong GQ, Liu QX, Luo JJ, Liu LX, Liu R, Qian S. The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. *BMC Cancer*. 2012;12:263.
38. Shao W, Zhang F, Cong N, Li J, Song J. Transarterial chemoembolization combined with sorafenib for

- advanced hepatocellular carcinoma. *Oncol Lett.* 2014;8:2263–6.
39. Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, Gog C, Lammert F, Schuchmann M, Walter C, Blondin D, Ohmann C, Häussinger D. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. *Cancer Chemother Pharmacol.* 2014;74:947–54.
40. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. *Oncologist.* 2012;17:359–66.
41. Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. *Int J Cancer.* 2015;136:1458–67.
42. Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. *PLoS One.* 2014;9:e91124.
43. Yang M, Yuan JQ, Bai M, Han GH. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. *Mol Biol Rep.* 2014;41:6575–82.
44. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterlo AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst.* 2000;92:205–16.
45. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. <http://evs.nci.nih.gov/ftp1/CTCAE/About.html>. Accessed 14 May 2015.
46. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. *Eur J Cancer.* 2011;47:2117–27.
47. Nishikawa H, Kita R, Kimura T, Osaki Y. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review. *Anticancer Res.* 2014;34:6877–86.
48. Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, Haj Mirzaian A, Najafi S, Shakiba M, Jalali AH. Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. *Hepat Mon.* 2014;14:e25792.
49. Raoul JL, Gilibert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. *Liver Cancer.* 2014;3:119–24.
50. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. *Cancer Treat Rev.* 2011;37:212–20.
51. Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score-based weighting. *J Dig Dis.* 2015;16:143–51.
52. Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ. *Oncology.* 2014;87:32–6.
53. Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. *Hepatol Res.* 2014;44:1179–85.